Related Experiment Video
Updated: Aug 6, 2026

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation
Published on: September 7, 2010
Inhibition of peptic activity by sucralfate
Abstract:
It is known that antacids containing aluminum hydroxide inhibit peptic activity by raising intragastric pH and by adsorbing pepsin. Since sucralfate contains aluminum hydroxide moieties, the possibility that this drug might inhibit peptic activity by these same mechanisms was examined. Sucralfate was incubated at a concentration of 10 mg/ml with samples of human gastric juice having pH values between 1.5 and 4 for 30 minutes at 37 degrees C. The proteolytic activity of the supernatant was then determined at a pH of 2.2 against a bovine hemoglobin substrate. When the initial pH of the gastric juice sample was 1.5, sucralfate was converted to a viscous gel and the pH of the incubation mixture rose to 2.9. However, there was no decrease in the peptic activity of the supernatant. In contrast, when the pH of the gastric juice sample was more than 2, the drug remained in suspension, but there was a graded rise in pH to a maximum of 4.1 and a progressive decrease in peptic activity (determined at a pH of 2.2) to a nadir of 65 percent of the control value. However, because peptic activity declines rapidly at a pH of more than 3, peptic activity at the ambient pH of the samples was reduced to only 25 percent of the control value. The results indicate that at pH values of more than 2, sucralfate inhibits peptic activity by both adsorbing pepsin and buffering hydrogen ions.
More Related Videos
10:24NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
Published on: June 30, 2019
03:05Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...